Welcome To Nutrify Snips
Nutra News made Easy
-
Silymarin Reduces Liver Stiffness in MASLD Patients by Modulating Gut Microbiota: A 24-Week Randomized Controlled Trial
A 24-week randomized, double-blind, placebo-controlled trial investigated the effect of silymarin on liver stiffness in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Eighty-three participants were divided between a silymarin group (103.2 mg/day) and a placebo group. Results showed that silymarin significantly reduced liver stiffness, γ-glutamyl transpeptidase (GGT), and ApoB levels compared to placebo. However,… Read More
-
Fermented Soybean: The New Superfood Fighting GERD and Reviving Quality of Life!
A recent study has shown that fermented soybean (FSB) supplementation may be an effective new treatment for gastroesophageal reflux disease (GERD), which impacts millions globally. Involving 110 participants over 12 weeks, the study required participants to take 1 gram of FSB daily, assessing symptoms with the Reflux Disease Questionnaire (RDQ) and measuring inflammatory markers such… Read More
-
Probiotics and the Gut-Brain Axis: A New Frontier in Mental Health Research
Recent studies suggest a promising role for probiotics in mental health, specifically through their impact on the gut-brain axis. Research shows that probiotics can modulate brain activity related to emotional regulation and cognitive processing, as revealed by task-based functional MRI studies. These findings extend to patients with major depressive disorder and irritable bowel syndrome (IBS),… Read More
-
The Synergistic Effects of Metabolaid and GLP-1 in Promoting Weight Loss.
A recent study has shown that Metabolaid, a natural blend of lemon verbena and hibiscus from Monteloeder, may significantly support weight loss efforts. Backed by 10 preclinical and clinical studies, Metabolaid has been linked to increased levels of GLP-1, a hormone crucial for regulating appetite and satiety. In a trial involving 61 overweight adults taking… Read More
-
FDA Approves Cobenfy: A Breakthrough Antipsychotic with New Mechanism for Schizophrenia Treatment
The FDA has approved Cobenfy (xanomeline and trospium chloride) for treating schizophrenia in adults, marking a breakthrough as the first antipsychotic to target cholinergic receptors instead of dopamine receptors. Schizophrenia, a chronic mental illness affecting about 1% of Americans, causes psychotic symptoms and cognitive difficulties, and is a leading cause of disability globally. Cobenfy’s efficacy… Read More